RESONATE-2: Ibrutinib benefits in older CLL/SLL patients sustained at 5 years
04 Apr 2020
byJairia Dela Cruz
The single-agent ibrutinib demonstrates significant and durable survival benefits compared with chlorambucil in the first-line treatment of older patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), including those with high-risk prognostic features, according to 5-year data from the RESONATE-2 study.